Also trades as: FRX.TO (TSX) · $vol 0M
FENC NASDAQ
Fennec Pharmaceuticals Inc.
1W: +1.5%
1M: -3.0%
3M: +10.1%
YTD: +38.3%
1Y: +18.1%
3Y: +56.0%
5Y: +19.5%
$10.62
+0.47 (+4.63%)
After Hours: $10.91 (+0.29, +2.78%)
Weekly Expected Move ±5.8%
$9
$9
$10
$11
$11
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -3.46.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-08-01
Earliest Filing
2024-03-21
Latest Filing
investor: 4
licensee: 1
Counterparties (Filed by FENC)
5 relationshipsCompanies named in FENC's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Norgine Pharma UK Limited | — | licensee | Granted exclusive license to commercialize PEDMARQSI® in the European Economic Area, Switzerland, the United Kingdom, Au | 2024-03-21 | View |
| Petrichor Opportunities Fund I LP | — | investor | Investor in a $5,000,000 third tranche of senior secured floating rate convertible notes. | 2023-12-06 | View |
| Petrichor Opportunities Fund I LP | — | investor | Investor in senior secured floating rate convertible notes financing transaction | 2022-09-26 | View |
| Petrichor Opportunities Fund I LP | — | investor | Investor in senior secured floating rate convertible notes financing transaction | 2022-08-22 | View |
| Petrichor Opportunities Fund I LP | — | investor | Investor in senior secured floating rate convertible notes issuance | 2022-08-01 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-17 | Other Events; Exhibits | View | |
| 2026-06-10 | Shareholder Vote | View | |
| 2026-05-22 | Other Events; Exhibits | View | |
| 2026-05-18 | Officer/Director Change; Exhibits | View | |
| 2026-04-28 | Officer/Director Change | View | |
| 2026-04-22 | Other Events; Exhibits | View | |
| 2026-04-07 | Other Events; Exhibits | View | |
| 2026-03-24 | Earnings Release; Exhibits | View | |
| 2026-03-16 | Other Events; Financial Statements and Exhibits | View | |
| 2026-03-04 | Other Events; Financial Statements and Exhibits | View | |
| 2026-02-20 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-02 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-19 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-18 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-17 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-06-03 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-07 | Other Events; Financial Statements and Exhibits | View | |
| 2024-12-20 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR